Vigeo Therapeutics to Present at the 2024 Glioblastoma Drug Development Summit in Boston Massachusetts

Cambridge MA – March 26, 2024 –Vigeo Therapeutics, a clinical-stage immuno-therapy company pioneering novel therapies to treat oncology and inflammatory diseases will be presenting at the Fifth Glioblastoma Drug Development Summit being held in Boston, Massachusetts from March 26-March 28, 2024.

Jing Watnick, COO of Vigeo Therapeutics, will be presenting a talk entitled “Leveraging Immune Checkpoint Inhibitors to Target the Tumor Microenvironment in Glioblastoma.” The talk provides an overview of the Ph1/2 First in Human study for VT1021, Vigeo’s lead program, as well as discusses the potential use of VT1021 to treat neuro-inflammatory diseases.

About Vigeo Therapeutics
Based in Cambridge Massachusetts, Vigeo Therapeutics is an immunotherapy company focused on developing therapies to fight cancer and inflammation. Vigeo is a leader in understanding the important role endogenous Thrombospondin-1 (TSP-1) plays in maintaining a healthy immune system. In many diseases (Oncology, Alzheimer’s disease, ALS and IBD), the immune system falters as TSP-1 levels drop, allowing disease to progress. Vigeo’s lead program, VT1021, is a small peptide derived from PSAP which induces TSP-1 production, restoring a healthier, more robust disease fighting immune system. For more information visit vigeotx.com.

« Back to Press Releases